Healthequity (HQY) EBITDA (2013 - 2026)

Healthequity's EBITDA history runs 14 years deep, the most recent figure standing at $103.0 million for Q2 2026.

• In Q2 2026, EBITDA rose 90.95% year-over-year to $103.0 million; the TTM figure through Apr 2026 stood at $342.3 million (up 181.05% YoY), while the FY2026 annual figure was $322.5 million, up 233.45% from the prior year.
• EBITDA was $103.0 million for Q2 2026 at Healthequity, up from $71.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $103.0 million in Q2 2026 to a low of -$32.8 million in Q1 2022.
• Historically, EBITDA has averaged $27.2 million across 5 years, with a median of $20.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA slumped 711.48% in 2022, then soared 12714.35% in 2024.
• A 5-year view of EBITDA shows it stood at -$1.6 million in 2022, then surged by 994.15% to $14.7 million in 2023, then plunged by 61.13% to $5.7 million in 2024, then surged by 1279.89% to $78.7 million in 2025, then soared by 30.83% to $103.0 million in 2026.
• The last three EBITDA figures came in at $103.0 million (Q2 2026), $71.1 million (Q1 2026), and $78.7 million (Q4 2025), per Business Quant data.